Estradiol/Norethindrone Acetate + Elagolix
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uterine Fibroids
Conditions
Uterine Fibroids, Heavy Menstrual Bleeding
Trial Timeline
Sep 14, 2016 → Mar 22, 2019
NCT ID
NCT02925494About Estradiol/Norethindrone Acetate + Elagolix
Estradiol/Norethindrone Acetate + Elagolix is a phase 3 stage product being developed by AbbVie for Uterine Fibroids. The current trial status is completed. This product is registered under clinical trial identifier NCT02925494. Target conditions include Uterine Fibroids, Heavy Menstrual Bleeding.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02925494 | Phase 3 | Completed |
Competing Products
20 competing products in Uterine Fibroids